Health
FDA Approves First Immunotherapy for Non-Surgical Rectal Cancer Treatment
The FDA has granted accelerated approval for the immunotherapy drug dostarlimab to treat a specific subset of locally advanced rectal cancer, potentially allowing patients to avoid surgery. Following successful clinical trials, this treatment targets tumors with DNA mismatch repair deficiencies by enabling the immune system to identify and eradicate cancer cells.